CEO of pSivida to discuss new technologies in retinal drug delivery at the San Diego Ophthalmic summit

Download PDF Copy

Sep 19 2009

NewsGuard 100/100 Score

pSivida Corp, (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery company, today announced that Dr. Paul Ashton, CEO, will lead a discussion on New Technologies in Retinal Drug Delivery at the 5^th Annual Ophthalmic Drug Development and Delivery Summit to be held September 21-22, 2009 in San Diego.

Dr. Ashton will describe the anatomical and technical difficulties of drug delivery to the retina; the advantages and disadvantages of earlier approaches to overcome these obstacles; current attempts to achieve effective dosing to the retina and provide an outlook on future developments in retinal delivery.

More information on the Summit can be found at its website: http://www.pharmedassociates.com.

www.psivida.com

Posted in: Pharmaceutical News

Tags: Cancer, Cytomegalovirus, Diabetic Macular Edema, Drug Delivery, Edema, Exercise, Pancreatic Cancer, Uveitis, VEGF

Comments (0)

Download PDF Copy

Suggested Reading

Squid-inspired technology could replace needles for medications and vaccines

Squid-inspired technology could replace needles for medications and vaccines

Nanotechnology could enhance traditional Chinese medicine delivery, promising improved clinical outcomes

Nanotechnology could enhance traditional Chinese medicine delivery, promising improved clinical outcomes

Tiny magnetic nanorobots show promise for treating brain aneurysms

Tiny magnetic nanorobots show promise for treating brain aneurysms

Small Solutions for Big Problems in Drug Discovery and Delivery

Small Solutions for Big Problems in Drug Discovery and Delivery

Aptamer extends agreement with genetic medicines customer

Aptamer extends agreement with genetic medicines customer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Overcoming adherence challenges: Innovative patch enables controlled drug delivery